

PTO/SB/08 (MODIFIED)

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/777,790
				Filing Date	02/11/2004
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	1646
Examiner Name					
Sheet	1	of	1	Attorney Docket Number	DX01040K3B

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
DJ	BJ	US-6,165,461	12-26-2000	Cobb et al.	
DJ	BK	US-6,632,624	10-14-2003	Degorce et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant, Passages or Relevant Figures Appear
		Country Code <sup>3</sup>	Number <sup>4</sup> Kind Code <sup>5</sup> (if known)			

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- issue number(s), publisher, city and/or country where published.		
DJ	BL	BENJAMINI <i>et al.</i> , "Antigency" Immunology, A Short Course, 2 <sup>nd</sup> ed., 1992 (John Wiley & Sons, Inc.), page 40.		
DJ	BM	RIECHMANN <i>et al.</i> (1988) <i>Nature</i> 332:323-327 "Reshaping human antibodies for therapy"		

Examiner Signature	/Dong Jiang/	Date Considered	02/03/2007
-----------------------	--------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1448/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		Application Number	10/777,790		
		Filing Date	02/11/2004		
		First Named Inventor	Jacqueline C. TIMANS		
		Art Unit	1846		
		Examiner Name			
Sheet	2	of	4	Attorney Docket Number	DX01040K3B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DJ	AC	Paulina BALBAS and Francisco BOLIVAR, <i>Methods in Enzymology</i> , 185:14-37, 1990. "[3] Design and Construction of Expression Plasmid Vectors in <i>Escherichia coli</i> "	
	AD	J. Fernando BAZAN, <i>et al.</i> , <i>NATURE</i> , 379:591, 15 February 1996. "A newly defined Interleukin-1?"	
	AE	S.L. BEAUCAGE and M.H. CARUTHERS, <i>Tetrahedron Letters</i> , 22(20):1859-1862, 1981. "DEOXYNUCLEOSIDE PHOSPHORAMIDITES - A NEW CLASS OF KEY INTERMEDIATES FOR DEOXYPOLYNUCLEOTIDE SYNTHESIS"	
	AF	M.F. BONALDO, <i>et al.</i> , <i>GenBank</i> , Accession No. AA875330, 4 July 1999. Definition: "UI-R-E0-cn-h-10-0-UI.s1 UI-R-E0 Rattus norvegicus cDNA clone UI-R-E0-cn-h-10-0-UI 3' similar to gij2847051[gb]AC002425[HUAC002425 Homo sapiens Chromosome 16 BAC clone CIT987SK-A-575C2, complete sequence [Homo sapiens], mRNA sequence"	
	AG	QI CHEN, <i>et al.</i> , <i>NATURE</i> , 407:916-920, 19 October 2000. "Development of Th1-type immune responses require the type 1 cytokine receptor TCCR"	
	AH	Q. CHEN, <i>et al.</i> , <i>GenBank</i> , Accession No. AF265242, 29 October 2000. Definition: "Homo sapiens type-I T cell cytokine receptor mRNA, complete cds.."	
	AI	Andreas D. CHRIST, <i>et al.</i> , <i>Gastroenterology</i> , 115:307-313, 1998. "An Interleukin 12-Related Cytokine Is Up-regulated in Ulcerative Colitis but Not in Crohn's Disease"	
	AJ	Odile DEVERGNE, <i>et al.</i> , <i>Proc. Natl. Acad. Sci. USA</i> , 94:12041-12046, October 1997. "Epstein-Barr virus-induced gene 3 and the p35 subunit of Interleukin 12 form a novel heterodimeric hematopoietin"	
	AK	Odile DEVERGNE, <i>et al.</i> , <i>GenBank</i> , Accession No. NM_005755, 29 June 2001. Definition: "Homo sapiens Epstein-Barr virus induced gene 3 (EBI3), mRNA."	
	AL	Alan D. ELBEIN, <i>Ann. Rev. Biochem.</i> , 56:497-534, 1987. "INHIBITORS OF THE BIOSYNTHESIS AND PROCESSING OF N-LINKED OLIGOSACCHARIDE CHAINS"	
	AM	Maurice K. GATELY, <i>et al.</i> , <i>Annu. Rev. Immunol.</i> , 16:495-521, 1998. "THE INTERLEUKIN-12/INTERLEUKIN-12-RECEPTOR SYSTEM: Role in Normal and Pathologic Immune Responses"	
	AN	Herve GROUX, <i>et al.</i> , <i>J. Exp. Med.</i> , 184:19-29, July 1996. "Interleukin-10 Induces a Long-Term Antigen-specific Anergic State in Human CD4+ T Cells"	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-6189 (1-800-789-9199) and select option 2.

PTO/SB/089 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/777,790
				Filing Date	02/11/2004
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	1646
				Examiner Name	
Sheet	3	of	4	Attorney Docket Number	DX01040K3B

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
DJ	AO	Shin-ichi HASHIMOTO, et al., <u>Immunobiology</u> , 96(6):2206-2214, 15 September 2000. "Identification of genes specifically expressed in human activated and mature dendritic cells through serial analysis of gene expression."		
	AP	Sten Eric W. JACOBSEN, <u>The Cytokine Handbook</u> , 3rd ed., Ch 13:365-367, Academic Press Ltd., 1998. "Interleukin-11: A Cytokine Signaling Through gp130 with Pleiotropic Effects and Potential Clinical Utility Within and Outside the Hematopoietic System"		
	AQ	Ross D. KING and Michael J.E. STERNBERG, <u>Protein Science</u> , 5:2298-2310, 1996. "Identification and application of the concepts important for accurate and reliable protein secondary structure prediction"		
	AR	Thomas A. KUNKEL, et al., <u>Methods in Enzymology</u> , 154:367-382, 1987. "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection"		
	AS	B.J. LOFTUS, et al., <u>GenBank</u> , Accession No. AC002544, 23 November 1999. Definition: "Homo sapiens Chromosome 16 BAC clone CIT887SK-A-781H5, complete sequence"		
	AT	LOFTUS, B.J., et al., "Genome duplications and other features in 12 Mb of DNA sequence from human chromosome 16p and 16q", Database GenEmbl on STN, Loculus HUAC002544 (GenEmbl, 23 November 1999).		
	AU	Verne A. LUCKOW and Max D. SUMMERS, <u>BIO/TECHNOLOGY</u> , 6:47-55, January 1988. "TRENDS IN THE DEVELOPMENT OF BACULOVIRUS EXPRESSION VECTORS"		
	AV	M. MARRA, et al., <u>GenBank</u> , Accession No. AA266872, 21 March 1997. Definition: "mz93a09.r1 Soares mouse lymph node NbMLN Mus musculus cDNA clone IMAGE:721000 5', mRNA sequence".		
	AW	NCI-CGAP, <u>GenBank</u> , Accession No. AI085007, 28 August 1998. Definition: "ow88d07.s1 Soares fetal liver spleen_1NFLS_S1 Homo sapiens cDNA clone IMAGE:1653901 3' similar to contains element MER22 repetitive element ;, mRNA sequence"		
	AX	Saul B. NEEDLEMAN and Christian D. WUNSCH, <u>J. Mol. Biol.</u> , 48:443-453, 1970. "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins"		
	AY	Birgit OPPMANN, et al., <u>Immunity</u> , 13:715-725, November 2000. "Novel p19 Protein Engages IL-12p40 to Form a Cytokine, IL-23, with Biological Activities Similar as Well as Distinct from IL-12"		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 603. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
<sup>1</sup>Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/089 (08-03)

Approved for use through 07/31/2008. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/777,780
				Filing Date	02/11/2004
				First Named Inventor	Jacqueline C. TIMANS
				Art Unit	1646
				Examiner Name	
Sheet	4	of	4	Attorney Docket Number	DX01040K3B

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
DJ	AZ	Patricia PARNET, <i>et al.</i> , <u>Journal of Biological Chemistry</u> , 271(8):3967-70, 1996. "IL-1Rrp Is a Novel Receptor-like Molecule Similar to the Type I Interleukin-1 Receptor and Its Homologues T1/ST2 and IL-1R AcP"	
	BA	Steven A. ROSENBERG, <u>Journal of Clinical Oncology</u> , 10(2):180-199, February 1992. "The Immunotherapy and Gene Therapy of Cancer"	
	BB	Burkhard ROST and Chris SANDER, <u>PROTEINS: Structure, Function and Genetics</u> , 19:55-72, 1994. "Combining Evolutionary Information and Neural Networks to Predict Protein Secondary Structure"	
	BC	Martin A. SCHWARTZ, <i>et al.</i> , <u>J. of Immunotherapy</u> , 16:93-104, 1994. "Stimulation of Cytokine Activity by Interleukin-10"	
	BD	Julie D. THOMPSON, <i>et al.</i> , <u>Nucleic Acids Research</u> , 25(24):4876-4882, 1997. "The CLUSTAL_X windows interface: flexible strategies for multiple sequence alignment aided by quality analysis tools"	
	BE	Giorgio TRINCHIERI, <u>Annu. Rev. Immunol.</u> , 13:251-276, 1995. "Interleukin-12: A Proinflammatory Cytokine With Immunoregulatory Functions That Bridge Innate Resistance And Antigen-Specific Adaptive Immunity"	
	BF	Giorgio TRINCHIERI, <u>Advances In Immunology</u> , 70:83-243, 1998. "Interleukin-12: A Cytokine at the interface of Inflammation and Immunity"	
	BG	Jean VIALLET and John D. MINNA, <u>Progress in Growth Factor Research</u> , 1:89-87, 1989. "Gastrin-Releasing Peptide (GRP, Mammalian Bombesin) In The Pathogenesis Of Lung Cancer"	
	BH	Slobodan VUKICEVIC, <i>et al.</i> , <u>Proc. Natl. Acad. Sci. USA</u> , 93:9021-26, August 1996. "Induction of Nephrogenic Mesenchyme by Osteogenic Protein 1 (bone morphogenetic protein 7)"	
	BI	Mair WILCHEK, <i>et al.</i> , <u>Methods In Enzymology</u> , 104:3-55, 1984. "[1] affinity Chromatography"	

Examiner Signature	/Dong Jiang/	Date Considered	02/03/2007
--------------------	--------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.  
 \*Applicant's unique citation designation number (optional). \*Applicant is to place a check mark here if English language Translation is attached.  
 This collection of information is required by 37 CFR 1.99. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-768-9199) and select option 2.